Foamix Pharmaceuticals (FOMX) IPOs 7.7M* shares @$6.00: http://finance.yahoo.com/news/foamix-pharmaceuticals-ltd-prices-initial-120000673.html Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne, impetigo and other skin conditions. Foamix Pharmaceuticals' lead product candidates, FMX101 for moderate-to-severe acne and FMX102 for impetigo, are novel topical foam formulations of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications. FOMX is up “only” 22% in the first hour of trading. *Assuming exercise of underwriter’s option.